Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Equity Method Investment (Details) € in Millions, £ in Millions		1 Months Ended		12 Months Ended
		Jul. 31, 2022 USD ($)	Jul. 31, 2022 GBP (£)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jul. 18, 2022	Jul. 03, 2022 USD ($)	Jul. 03, 2022 GBP (£)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 EUR (€)	Mar. 31, 2022 GBP (£)	May 31, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jul. 31, 2019	Dec. 31, 2016 USD ($)
Schedule of Equity Method Investments [Line Items]
Equity-method investments				$ 11,033,000,000	$ 16,472,000,000
Dividend received, return of capital	[1]			3,960,000,000	0	$ 0
Other short-term borrowings	[2]			385,000,000	605,000,000
Senior Notes [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount													$ 4,000,000,000	$ 1,250,000,000
1.365% Consumer Healthcare JV Loan [Member] | Loans Payable
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount | £									£ 2,900
Other short-term borrowings								$ 3,700,000,000
Stated interest rate								1.365%	1.365%
Repurchased debt | £			£ 2,900
Haleon/Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage							32.00%			32.00%	32.00%	32.00%				32.00%
Equity-method investments				10,800,000,000	16,300,000,000
Equity-method investment, quoted market value				11,700,000,000
Dividends received, total		$ 4,200,000,000	£ 3,500	4,500,000,000
Dividend received, return of capital		$ 4,000,000,000		4,000,000,000
Dividend received, distribution				584,000,000
Decrease due to foreign currency translation				1,400,000,000
Equity method investment earnings				536,000,000	495,000,000	417,000,000
Equity method investment, adjustment of basis differences				$ 100,000,000
Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Difference between carrying amount and underlying equity															$ 4,800,000,000
ViiV [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage				11.70%
Equity-method investments																	$ 0
Dividend income				$ 314,000,000	$ 166,000,000	$ 278,000,000
GSK [Member] | Haleon/Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage																68.00%
Haleon/Consumer Healthcare JV [Member] | Senior Notes, USD Denominated [Member] | Senior Notes [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount										$ 8,750,000,000
Haleon/Consumer Healthcare JV [Member] | Senior Notes, EUR Denominated [Member] | Senior Notes [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount | €											€ 2,350
Haleon/Consumer Healthcare JV [Member] | Senior Notes, GBP Denominated [Member] | Senior Notes [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount | £												£ 700
Haleon/Consumer Healthcare JV [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | GSK [Member]
Schedule of Equity Method Investments [Line Items]
Proposed percent of ownership disposal										80.00%	80.00%	80.00%
Minimum [Member] | Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Excess basis amortization period				8 years
Maximum [Member] | Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Excess basis amortization period				20 years

[1] See Note 2C.

[2] Primarily includes cash collateral. See Note 7F.